These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36266621)

  • 1. Unmet needs about iron deficiency in peritoneal dialysis: a Delphi consensus panel.
    Mazzaferro S; D'Alonzo S; Morosetti M
    BMC Nephrol; 2022 Oct; 23(1):336. PubMed ID: 36266621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
    Rognoni C; Ortalda V; Biasi C; Gambaro G
    Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A; Mircescu G
    Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N.
    Portolés J; Martín-Malo A; Martín-Rodríguez L; Fernández-Fresnedo G; De Sequera P; Emilio Sánchez J; Ortiz-Arduan A; Cases A;
    Nefrologia (Engl Ed); 2023; 43(5):517-530. PubMed ID: 37993379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
    Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
    Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis.
    Wong G; Howard K; Hodson E; Irving M; Craig JC
    Nephrol Dial Transplant; 2013 Feb; 28(2):413-20. PubMed ID: 23182811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC
    Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
    BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
    Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
    Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center.
    Gobbi L; Scaparrotta G; Rigato M; Cattarin L; Qassim L; Carraro G; Rossi B; Calò LA
    Ther Apher Dial; 2020 Dec; 24(6):642-647. PubMed ID: 32154642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.